Approaches targeting the modulation of Bcl-2 and Bcl-XL expression and activity have been shown to hold considerable potential in overcoming resistance by sensitizing cancer cells to Tx-induced apoptosis [35, 36]. The gene discussed is BCL2; the disease is cancer.